Inactive Instrument

All News LENZ Therapeutics, Inc. OTC Markets

Equities

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	05-08	GL
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024	05-01	GL
Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	04-15	MT
William Blair Starts LENZ Therapeutics With Outperform Rating	04-15	MT
LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials	04-03	MT
LENZ Therapeutics, Inc. Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials	04-03	CI
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study	04-03	RE
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials	04-03	BU
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials	04-02	BU
Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target	03-27	MT
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to NASDAQ Composite Index	03-24	CI

No results for this search